Clovis Oncology, Inc. (CLVS) stock rallied over 58.33% intraday to trade at $2.85 a share on NASDAQ. The stock opened with a gain of 69.64% at $1.78 and touched an intraday high of $2.9, rising 58.33% against the last close of $1.8. The stock went to a low of $1.78 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue148.76 Million
5Y Sales Change353.00%
Fiscal Year Ends2021-12-30
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
Clovis Oncology, Inc. (NASDAQ: CLVS) stock price is $2.85 as of the last check on Friday, July 1. During the trading session, CLVS stock reached the peak price of $2.9 while $1.78 was the lowest point it dropped to.
The NASDAQ listed CLVS is part of Biotechnology industry that operates in the broader Health Care sector. Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
Dr. Gillian C. Ivers-Read
Co-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations
Mr. Patrick J. Mahaffy MA
Co-Founder, CEO, Pres & Exec. Director
Dr. Gillian C. Ivers-Read BSc
Co-Founder, Exec. VP & Chief Regulatory Officer
Mr. Daniel W. Muehl
Exec. VP & CFO
CLVS stock traded closed the last session at $2.85, which is $1.05 or 58.33% lower than its previous close of $1.8. CLVS's current trading price is 390.53% lower than its 52-week high of $5.92 where as its distance from 52-week low of 0.58% is -51.86%.
Number of CLVS employees currently stands at -. CLVS operates from 5500 Flatiron Parkway, Suite 100, Boulder, CO 80301, United States.
Official Webiste of $CLVS is: https://www.clovisoncology.com
CLVS stock volume for the day was 75,260,446 shares while in the previous session number of CLVS shares traded was 75,854,400 . The average number of CLVS shares traded daily for last 3 months was 16.2 Million.
The percentage change in CLVS stock occurred in the recent session was 58.33% while the dollar amount for the price change in CLVS stock was $1.05.
In the recent session, the day high for CLVS stock was $2.9 while the low for CLVS stock touched on the day was $1.78.
The market value of CLVS currently stands at 259.01 Million with its latest stock price at $2.85 and 138.21 Million of its shares outstanding.